Small-molecule-mediated targeted protein degradation (TPD) relies on the recruitment of a target protein of interest to an E3 ligase. A new study indicates how direct target recruitment to the 26S proteasome can bypass this requirement.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Hanzl, A. et al. Curr. Opin. Chem. Biol. 56, 35–41 (2020).
Bashore, C. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-022-01218-w (2022).
Békés, M. et al. Nat. Rev. Drug Discov. 21, 181–200 (2022).
Jan, M. et al. Nat. Rev. Clin. Oncol. 18, 401–417 (2021).
Gooding, S. et al. Blood. 137, 232–237 (2021).
Murakami, Y. et al. Nature. 360, 597–599 (1992).
Finley, D. et al. Cold Spring Harb. Perspect. Biol. 12, a033985 (2020).
Schneider, M. et al. Nat. Rev. Drug Discov. 20, 789–797 (2021).
Ng, C. et al. Curr. Opin. Chem. Biol. 67, 102107 (2022).
G.E.W. is scientific founder and shareholder of Proxygen and Solgate. The Winter lab receives research funding from Pfizer.
About this article
Cite this article
Tin, G., Winter, G.E. CIDE-stepping E3s. Nat Chem Biol 19, 3–4 (2023). https://doi.org/10.1038/s41589-022-01217-x